Comment on “Levothyrox(®) New and Old Formulations: Are They Switchable for Millions of Patients?”

por Munafo, Alain, Krebs-Brown, Axel, Gaikwad, Sumedh, Urgatz, Bogumila, Castello-Bridoux, Claire
Publicado 2019

Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

por Krebs-Brown, Axel, Munafo, Alain, Gaikwad, Sumedh, Urgatz, Bogumila, Castello-Bridoux, Claire
Publicado 2019